ARTL · Insider Trading
Artelo Biosciences, Inc. Common Stock
Every open-market purchase and sale reported by ARTL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-21 | Douglas Blayney | Director | A | +136 deriv. | — |
| 2026-07-21 | Gregory Reyes | Director | A | +136 deriv. | — |
| 2026-07-21 | Robert Martin Emanuele | Director | A | +136 deriv. | — |
| 2026-07-21 | Tamara A Favorito | Director | A | +136 deriv. | — |
| 2026-07-21 | Steven Kelly | Director | A | +136 deriv. | — |
| 2026-07-21 | Connie Matsui | Director | A | +136 deriv. | — |
| 2026-02-02 | Douglas Blayney | Director | A | +292 deriv. | — |
| 2026-02-02 | Steven Kelly | Director | A | +292 deriv. | — |
| 2026-02-02 | Gregory D. Gorgas | Pres, CEO, CFO, Treas & Secr | A | +154,713 deriv. | — |
| 2026-02-02 | Tamara A Favorito | Director | A | +292 deriv. | — |
| 2026-02-02 | Gregory Reyes | Director | A | +292 deriv. | — |
| 2026-02-02 | Robert Martin Emanuele | Director | A | +292 deriv. | — |
| 2026-02-02 | Connie Matsui | Director | A | +292 deriv. | — |
| 2026-02-02 | Mark Edward Spring | Chief Financial Officer | A | +36,391 deriv. | — |
| 2025-10-30 | Connie Matsui | Director | C | +108,722 deriv. | — |
| 2025-10-30 | Gregory D. Gorgas | President, CEO, Treasurer, Sec | C | +27,538 deriv. | — |
| 2025-10-30 | Tamara A Favorito | Director | C | +19,412 deriv. | — |
| 2025-07-07 | Gregory D. Gorgas | President, CEO, CFO, Treasurer | A | +40,393 deriv. | — |
| 2025-05-05 | Connie Matsui | Director | Buy | — | — |
| 2025-05-05 | Tamara A Favorito | Director | Buy | — | — |
| 2025-05-05 | Gregory D. Gorgas | Pres, CEO, CFO, Treas & Secr | Buy | — | — |
| 2024-12-23 | Connie Matsui | Director | A | +1,750 deriv. | — |
| 2024-12-23 | Robert Martin Emanuele | Director | A | +1,750 deriv. | — |
| 2024-12-23 | Douglas Blayney | Director | A | +1,750 deriv. | — |
| 2024-12-23 | Gregory Reyes | Director | A | +1,750 deriv. | — |
| 2024-12-23 | Steven Kelly | Director | A | +1,750 deriv. | — |
| 2024-12-23 | Tamara A Favorito | Director | A | +1,750 deriv. | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ARTL quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.